News

Gilbert Wagener Appointed Interim CMO at Cell2B

28 April 2014 — FacebookLinkedInEmail
Gilbert Wagener

Cell2B appointed Gilbert Wagener (MD, PhD, MBA) as interim Chief Medical Officer. This appointment is crucial for the transition to clinical development of Cell2B’s leading product ImmuneSafe. Dr. Wagener will be responsible for clinical development and clinical trial operations. Dr. Wagener has a long career in the industry with a focus on clinical development for oncology, cardiovascular, and CNS indications, including stem cell-based therapies. Dr Wagener is a Partner at Transcrip Partners in Reading, UK. Before joining Cell2B, he was VP of Genzyme Europe B.V. in different areas for 16 years and he was director for global cardiovascular clinical strategy at Bayer Healhcare AG.